Published • loading... • Updated
Kanvas Biosciences Raises $48M to Advance Spatial Biology Platform and Immuno-Oncology Trials
Summary by hitconsultant.net
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Kanvas Biosciences Raises $48M to Advance Spatial Biology Platform and Immuno-Oncology Trials
What You Should Know Kanvas Biosciences has raised $48M in Series A funding co-led by DCVC and Lions Capital LLC, bringing total funding to $78M.The capital will fund clinical trials for KAN-001, an immuno-oncology drug candidate designed for cancer patients who do not respond to immune checkpoint inhibitors (ICIs).The company utilizes a unique spatial mapping platform to visualize microbial and host cell interactions, overcoming traditional roa…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
